Trial Radar AI

Let's discuss and explore clinical trials with Syndax Pharmaceuticals as a lead sponsor or collaborator.

I can help you find nearby clinical trials and understand health conditions and treatments.
14 Clinical Trials
Study Title
Status
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia NCT07283640
Not yet recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation (REVEAL-ND NPM1) NCT07211958
Recruiting
Revumenib in Combination With 7+3 + Midostaurin in AML NCT06313437
Recruiting
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib NCT06284486
Recruiting
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes NCT06229912
Recruiting
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias NCT06226571
Recruiting
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia NCT06177067
Recruiting
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) NCT06132256
Recruiting
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) NCT05360160
Recruiting
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201) NCT04710576
Active, not recruitingResults Posted
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) NCT04065399
Recruiting
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer NCT03978624
Active, not recruitingResults Posted
High Dose IL 2 and Entinostat in RCC NCT03501381
Active, not recruiting
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas NCT03179930
Active, not recruiting